Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neluxicapone
- Development stage
- Phase 2
- Lead developer
- Orion
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Neluxicapone (also known as ODM-104) is a reversible, peripherally-acting inhibitor of the enzyme catechol-O-methyltransferase (COMT). Developed by Orion Corporation, it was designed as an adjunctive treatment for patients with Parkinson's disease who experience motor fluctuations while taking levodopa. By inhibiting COMT, neluxicapone prevents the peripheral breakdown of levodopa into 3-O-methyldopa, thereby increasing the plasma half-life and bioavailability of levodopa. This allows for more consistent levels of levodopa to cross the blood-brain barrier, effectively extending the therapeutic 'on' time and reducing 'off' periods in patients. It has been primarily investigated in fixed-dose combination formulations alongside levodopa and a DOPA decarboxylase inhibitor like carbidopa.
- Other names
- neluxicapone
02
Targets
COMT (Catechol-O-methyltransferase)
Beyond the preview
Go deeper on neluxicapone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neluxicapone.